Vaccinex Announces Wednesday July 8 It Will Present New Glial Biomarker Data From the Phase 1/2 SIGNAL-AD Study of Pepinemab (Anti-Semaphorin 4D Humanized IgG4 Monoclonal Antibody) at the Alzheimer's Association International Conference in London on July 13, 2026 Alongside Plans for the Expanded Randomized Phase 2B SIGNAL-AD2 Trial: Elizabeth Evans, PhD (COO/SVP Discovery and Translational Medicine) Will Chair the Featured Research Session
Vaccinex (NASDAQ: VCNX) announced Wednesday July 8, 2026 that it will present new glial biomarker data from the Phase 1/2 SIGNAL-AD study of pepinemab and plans for the expanded Phase 2B SIGNAL-AD2 trial at the Alzheimer's Association International Conference (AAIC) 2026 in London on July 13. Elizabeth Evans, PhD, Chief Operating Officer and Senior VP of Discovery and Translational Medicine, will chair the Featured Research Session. Pepinemab is a humanized IgG4 monoclonal antibody targeting Semaphorin 4D (SEMA4D). The mechanism blocks SEMA4D signaling through astrocyte plexin-B1 receptors, reducing reactive astrocyte activation and downstream neuroinflammation — a disease-modifying approach mechanistically distinct from amyloid- or tau-targeting strategies. Pepinemab is a monoclonal antibody rather than a peptide, but the SEMA4D program sits in the peptide-and-biologic neurodegeneration territory this site tracks alongside the Vera Therapeutics Trutakna (atacicept fusion protein) approval covered yesterday. AAIC readouts to watch: cerebrospinal-fluid glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) biomarker shifts on pepinemab treatment.